FDA Approves New RSV Drug to Protect Infants and Young Children
TL;DR Summary
The FDA has approved a new drug called Beyfortus for the prevention of respiratory syncytial virus (RSV) in babies and toddlers. RSV is a common cause of childhood illness and can lead to serious complications. Beyfortus, created by Sanofi and AstraZeneca, is a preventive drug that delivers long-acting antibodies to provide protection during RSV season. Clinical trials have shown that Beyfortus reduces the risk of RSV in infants and children by 70 to 75%. The drug is expected to be available in the U.S. before the 2023-2024 RSV season.
- The FDA approved a new RSV drug for babies and young children. Here's what parents need to know. Yahoo Life
- New drug to protect babies and toddlers from RSV gets FDA approval ahead of cold season KPRC 2 Click2Houston
- FDA approves antibody to protect infants from RSV CNN
- FDA approves RSV antibody for infants 11Alive
- FDA approves vaccine-like RSV shot for infants Salon
Reading Insights
Total Reads
0
Unique Readers
10
Time Saved
3 min
vs 4 min read
Condensed
86%
625 → 89 words
Want the full story? Read the original article
Read on Yahoo Life